<a href="https://laohu8.com/S/EVH">Evolent Health Inc</a>. Announces $166.75 Million Convertible Senior Notes Issuance in Latest Financing Agreement
Evolent Health Inc. announced on August 18, 2025, that it has entered into a purchase agreement with Oppenheimer & Co. Inc., representing several initial purchasers, for the issuance and sale of $145 million in 4.50% convertible senior notes due 2031. This transaction marks a significant step in Evolent Health's financial strategy, as the notes were issued via a private placement to qualified institutional buyers under Rule 144A of the Securities Act. The company also conducted concurrent note repurchases totaling approximately $167.6 million and repurchased around $40 million in Class A common stock. The agreement includes customary representations, warranties, and indemnification rights, and the notes were issued under an Indenture dated the same day.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Evolent Health Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001193125-25-185388), on August 21, 2025, and is solely responsible for the information contained therein.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.